Citi analyst Joanne Wuensch upgraded Penumbra (PEN) to Buy from Neutral with a price target of $350, up from $285. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is “bouncing off its lows,” and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index “remains undervalued and underappreciated.” The firm expects a rebound next year due to company catalysts and sector rotation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra’s Promising Growth: Buy Rating Backed by Strong Portfolio and Technological Advancements
- Penumbra’s Promising Growth: Buy Rating Backed by STORM-PE Trial and Market Expansion
- Penumbra Inc. Reports Strong Q3 Growth Amid Challenges
- Penumbra price target raised to $286 from $285 at Evercore ISI
- Penumbra’s Hold Rating: Balancing Recent Success with Future Uncertainties